CalciMedica shares surge 14.24% premarket after resolving KOURAGE trial safety concerns and advancing acute pancreatitis program design.

CalciMedica surged 14.24% in premarket trading following the announcement that internal and external reviews of its Phase 2 KOURAGE trial for acute kidney injury found no evidence of drug-related toxicity with Auxora. The company also highlighted progress in its acute pancreatitis program, including FDA engagement and the publication of Phase 2b CARPO trial results showing Auxora’s efficacy in reducing severe respiratory failure and organ failure. Additionally, preclinical data for CM5480 in pulmonary arterial hypertension were cited, with an IND submission expected in 2027. These updates addressed prior safety concerns, reinforced the pipeline’s potential, and aligned with the stock’s upward movement, overshadowing broader liquidity risks and capital-raising activities mentioned in other reports.